Novartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen's technology for turning intravenous biologics ...

French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a ...

Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 ...

A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to ...

Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a ...

Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another ...

Swiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its lead anti-Nogo-A antibody into a randomized proof-of-concept study in ...

Novartis has paused eight clinical trials of its CD19 CAR-T therapy rap-cel after three patients died from a severe immune reaction. The studies are evaluating the therapy in autoimmune and ...

Swiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models ...

California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic ...

About the author: Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics and director of the RNA Innovation Center at Johns Hopkins University. He serves on the board of ...

Last weekend, from August 28 to 31, the European Society of Cardiology (ESC) held its annual congress in Munich. For the biotech industry, ESC 2026 delivered a mixed bag: a cardiac myosin inhibitor ...